Views & Analysis Patient involvement in HTA Considering the essential role of patient experience in HTA and the role of pharma.
Views & Analysis The honest broker in market access Eric Low shares his views on why hurdles remain to new drug access.
Views & Analysis Mind the (implementation) gap Examining the true impact of a positive health technology assessment (HTA).
Views & Analysis Orphan drugs: overcoming barriers to market access What manufacturers should consider, after successfully overcoming any HTA hurdles, to achieve market access.
Views & Analysis Orphan drugs: overcoming HTA barriers to access How can orphan drug manufacturers demonstrate value and improve access to drugs?
Views & Analysis Demonstrating value – the future for market access With the US joining other countries around the world in demanding definitions and measurements of the value of treatments, the pharma industry faces the challenge of understanding the requireme
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
